00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
23:43 , Mar 27, 2019 |  BC Extra  |  Financial News

Gene therapy company Prevail raises $50M series B

Prevail raised $50 million in a series B round to advance its pipeline of gene therapies for neurodegenerative diseases. Existing investors participating in the round included OrbiMed Advisors, Pontifax, RA Capital Management, EcoR1 Capital, Omega...
13:25 , Feb 8, 2019 |  BioCentury  |  Emerging Company Profile

Palleon: Sweeter checkpoints

With two platforms targeting glycan ligands and their receptors, and a third to match cancer patients to a therapy, Palleon Pharmaceuticals Inc. aims to treat cancer by removing the brakes on a class of checkpoints...
23:41 , Feb 7, 2019 |  BC Innovations  |  Finance

Pharma ventures earlier

Facing the squeeze from inside and out, at least three corporate venture arms are revamping operations to increase their foothold in earlier and riskier investment opportunities. From one side, the move reflects the growing reliance...
21:35 , Jan 11, 2019 |  BioCentury  |  Emerging Company Profile

Artios: Probing DNA Damage

With programs in-licensed from Cancer Research UK and Masaryk University, Artios Pharma Ltd. thinks it has next-generation DNA damage response programs that could improve upon PARP inhibitors -- and the funds to take them to...
19:39 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Ribon raises $65M series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis...
12:01 , Jan 4, 2019 |  BC Extra  |  Financial News

Ribon raises $65 million series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis...